Newlink Genetics reported -8664000 in Operating Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agenus AGEN:US $ -66.4M 25.02M
Bristol Myers Squibb BMY:US $ 1715M 36M
Capricor Therapeutics CAPR:US $ -4.76M 0.4M
Celldex Therapeutics CLDX:US $ -13.44M 3.2M
Eli Lilly And LLY:US $ 1403.4M 248.1M
Idera Pharmaceuticals IDRA:US $ -7.56M 2.47M
Intrexon XON:US $ -15.67M 2.01M
Merk MRK:US $ 1497M 1517M
Nektar Therapeutics NKTR:US $ -110.2M 0.81M
Newlink Genetics NLNK:US -8664000 47K
Pfizer PFE:US $ 5914M 397M
Prothena PRTA:US 27.95M 60.06M
Sarepta Therapeutics SRPT:US $ -167.57M 15.71M
Vascular Biogenics VBLT:US -8024000 1.68M
YTE INCY:US $ 140.84M 42.04M